ecancermedicalscience

Clinical Study

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

26 Nov 2014
Pan Pantziarka, Gauthier Bouche, Lydie Meheus, Vidula Sukhatme, Vikas P Sukhatme

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

Article metrics: 32825 views
7734
25091

Related Articles

Eugenia Cordero-García, Andrés Baéz-Astúa, Yolanda Roa-Martínez, Vanessa Ramírez-Mayorga, Warner Alpízar-Alpízar
Tiffany G Sheu, Kai Sun, Ryan J Reynolds, Jessica A Tomsula, Lara Colton, Lawrence Rice
Rodrigo Ramella Munhoz, Gilberto de Castro Jr, Gustavo Duarte Ramos Matos, Veridiana Pires de Camargo